Ahlim Lee

Ahlim Lee

Auto-generated profile, based on publicly available information

Ahlim Lee

The Catholic University Liver Research Center, Department of Biomedicine & Health Sciences, College of Medicine The Catholic University of Korea Seoul Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JHJi Won Han
Ji Won Han
SLSoon Kyu Lee
Soon Kyu Lee
JKJung Hyun Kwon
Jung Hyun Kwon
SNSOON WOO Nam
SOON WOO Nam
HYHyun Yang
Hyun Yang
Jeong Won JangJeong Won Jang
Jeong Won Jang
Purpose: Given its heterogeneity and diverse clinical outcomes, precise subclassification of Barcelona Clinic Liver Cancer stage C (BCLC-C) hepatocellular carcinoma (HCC) is required for appropriately determining patient prognosis and selecting treatment. Experimental Design: We recruited 2,626 patients with BCLC-C HCC from multiple centers, comprising training/test (n = 1,693) and validation cohorts (n = 933). The XGBoost model was chosen for maximum performance among the machine learning (ML) models. Patients were categorized into low-, intermediate-, high-, and very high-risk subgroups based on the estimated prognosis, and this subclassification was named the CLAssification via Machine learning of BCLC-C (CLAM-C). Results: The areas under the receiver operating characteristic curve of the CLAM-C for predicting the 6-, 12-, and 24-month survival of patients with BCLC-C were 0.800, 0.831, and 0.715, respectively—significantly higher than those of the conventional models, which were consistent in the validation cohort. The four subgroups had significantly different median overall survivals, and this difference was maintained among various patient subgroups and treatment modalities. Immune-checkpoint inhibitors and transarterial therapies were associated with significantly better survival than tyrosine kinase inhibitors (TKI) in the low- and intermediate-risk subgroups. In cases with first-line systemic therapy, the CLAM-C identified atezolizumab–bevacizumab as the best therapy, particularly in the high-risk group. In cases with later-line systemic therapy, nivolumab had better survival than TKIs in the low-to-intermediate-risk subgroup, whereas TKIs had better survival in the high- to very high-risk subgroup. Conclusions: ML modeling effectively subclassified patients with BCLC-C HCC, potentially aiding treatment allocation. Our study underscores the potential utilization of ML modeling in terms of prognostication and treatment allocation in patients with BCLC-C HCC.

18 July 2024 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KYKeungmo Yang
Keungmo Yang
HYHyun Yang
Hyun Yang
CKChang Wook Kim
Chang Wook Kim
HNHeechul Nam
Heechul Nam
JKJi Hoon Kim
Ji Hoon Kim
HKHee Yeon Kim
Hee Yeon Kim
Keungmo Yang, Hyun Yang, Chang Wook Kim, Hee Chul Nam, Ji Hoon Kim, Ahlim Lee, U Im Chang, Jin Mo Yang, Hae Lim Lee, Jung Hyun Kwon, Soon Woo Nam, Soon Kyu Lee, Pil Soo Sung, Ji Won Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hee Yeon Kim. Gut and Liver 2024;18:877-87. https://doi.org/10.5009/gnl240032

31 March 2022 in Journal of Liver Cancer
Verified
Journal Article
Open access
PDF file
ALAhlim Lee
Ahlim Lee
JLJaejun Lee
Jaejun Lee
HYHyun Yang
Hyun Yang
SSSoo-Yoon Sung
Soo-Yoon Sung
CJChang Ho Jeon
Chang Ho Jeon
SBSi Hyun Bae
Si Hyun Bae
Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therapeutic outcomes were unsatisfactory in more than half of the patients. Accordingly, many ongoing trials combine conventional modalities with new drugs such as immune checkpoint inhibitors for better treatment outcomes, and they are expected to benefit patients with limited responses to conventional treatment. Here, two patients with advanced stage HCC with preserved liver function and good performance status showed partial response after treatment with combination or sequential therapy of AteBeva, hepatic arterial infusion chemotherapy, radiation therapy, and transarterial chemoembolization. These findings indicate the efficacy of multidisciplinary treatment against advanced HCC. Additional studies are required to establish optimal treatment strategies.

11 April 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JLJihye Lim
Jihye Lim
JKJi Hoon Kim
Ji Hoon Kim
ALAhlim Lee
Ahlim Lee
JHJi Won Han
Ji Won Han
SLSoon Kyu Lee
Soon Kyu Lee
MSMyeong Jun Song
Myeong Jun Song
Jihye Lim, Ji Hoon Kim, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hae Lim Lee, Do Seon Song, Sung Won Lee, Hee Yeon Kim, Jung Hyun Kwon, Chang Wook Kim, U Im Chang, Soon Woo Nam, Seok-Hwan Kim, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Myeong Jun Song. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240584

23 May 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JLJaejun Lee
Jaejun Lee
KYKeungmo Yang
Keungmo Yang
JHJi Won Han
Ji Won Han
PSPil Soo Sung
Pil Soo Sung
Jeong Won JangJeong Won Jang
Jeong Won Jang
SLSoon Kyu Lee
Soon Kyu Lee
Purpose: Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims to evaluate the treatment’s efficacy in this population and identify specific CPS 7 subgroups that may benefit from it. Experimental Design: This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response. Results: Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients with CPS 6 (n = 105) and CPS 7 (n = 100; P < 0.05). For the variables comprising CPS, the HR for OS increased with elevated total bilirubin levels and was lower in patients with mild ascites (P < 0.05). The HR for OS tended to increase as albumin levels dropped to 2.8 g/dL. Based on these findings, patients with CPS 7 were further classified into two subgroups: favorable (total bilirubin <2 mg/dL, 3.5 ≥ albumin ≥ 2.8 g/dL, mild ascites, and absence of hepatic encephalopathy) and unfavorable (other CPS 7). Compared with patients with CPS 6, those in the favorable CPS 7 group exhibited comparable OS and PFS, whereas patients with unfavorable CPS 7 had significantly lower OS and PFS (P < 0.05). These findings were consistently observed in the multivariate analysis. Conclusions: This study suggests that Ate/Bev treatment can be effective in a subset of patients with CPS 7, highlighting the potential to broaden treatment eligibility for this population. See related commentary by Li and Kelley, p. 4220

11 August 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
ALAhlim Lee
Ahlim Lee
CHChang In Han
Chang In Han
KYKeungmo Yang
Keungmo Yang
HYHyun Yang
Hyun Yang
PSPil Soo Sung
Pil Soo Sung
JLJaejun Lee
Jaejun Lee
Background: Although numerous noninvasive indices have been proposed to assess significant fibrosis (SF), none have been validated specifically in young adults with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study evaluated their performance in younger patients across two cohorts with distinct screening goals. Methods: We retrospectively analyzed two MASLD cohorts: a primary care (PC) cohort ( n = 972) and a tertiary care (TC) cohort ( n = 342). SF was defined as liver stiffness ≥ 7.0 kPa on vibration‐controlled transient elastography. The diagnostic performance of emerging indices—fibrosis‐8 index, steatosis‐associated fibrosis estimator, metabolic‐associated fibrosis score‐5—was compared with traditional scores—fibrosis‐4 index, aspartate aminotransferase‐to‐platelet ratio index, and nonalcoholic fatty liver disease fibrosis score. Results: Across both settings, emerging indices consistently outperformed traditional scores for SF discrimination. The areas under the receiver operating characteristic curves were higher for the emerging indices than for the traditional indices in both cohorts. Decision curve analyses demonstrated that emerging indices provided greater net clinical benefit and larger reductions in unnecessary procedures, with thresholds differing by setting such that lower thresholds favored referral in the PC cohort, whereas higher thresholds were more appropriate for biopsy decisions in the TC cohort. Conventional cutoffs widely used in practice demonstrated limited sensitivity in this population, suggesting that refinement may be required. Conclusions: Traditional noninvasive fibrosis indices showed limited performance in young adults with MASLD, whereas emerging indices appeared more suitable for achieving the screening goals of referral in PC and biopsy decision‐making in TC.